Association between daily insulin Dose, cancer Incidence, and mortality in type 1 diabetes patients
Authors' conclusion
Higher insulin doses may protect against cancer and reduce mortality, likely due to improved glycemic control. While insulin's mitogenic effects raise concerns, poor glycemic control itself is a known cancer risk factor. These findings suggest that optimizing insulin therapy in type 1 diabetes may outweigh potential oncogenic risks. Future research should validate these results in broader populations and explore underlying mechanisms to refine insulin dosing strategies for improved long-term outcomes.
Study context
- Population
- Patients with T1D, Taiwan's National Health Insurance Research Database and Cancer Registry
- Participants
- 10,248 patients
- Exposure
- Higher vs lower daily insulin dose
- Outcome
- Cancer incidence and all-cause mortality
Methodological detailsCox proportional hazards models, sensitivity analyses using Poisson regression
- Cox proportional hazards models
- Sensitivity analyses using Poisson regression
Main finding
As reported in the abstract
Cancer risk lower with higher insulin doses: HR
0.42 (0.28-0.64) (95% CI)
All-cause mortality reduced with higher insulin doses: HR
0.35 (0.26-0.49) (95% CI)
Observational data: associations, not effects.
Further findings
- Sensitivity analyses confirmed these findings
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →